PainReform Ltd. (PRFX): Price and Financial Metrics
GET POWR RATINGS... FREE!
PRFX Stock Price Chart Interactive Chart >
PRFX Price/Volume Stats
| Current price | $0.44 | 52-week high | $1.79 |
| Prev. close | $0.45 | 52-week low | $0.41 |
| Day low | $0.43 | Volume | 1,900 |
| Day high | $0.45 | Avg. volume | 53,363 |
| 50-day MA | $0.59 | Dividend yield | N/A |
| 200-day MA | $0.85 | Market Cap | 4.68M |
PainReform Ltd. (PRFX) Company Bio
PainReform Ltd. operates as a pharmaceutical company. It develops and markets pharmaceuticals. The firm focuses on developing reformulation of pain therapeutics, PainReform applies its propriety formulation technologies to prolong and enhance efficacy, reduce adverse effects shortening recovery time and reduce the need of augmentation with drugs such as opioids and NSAIDS. The company was founded by Lihu Avitov and Dan Teleman in 2007 and is headquartered in Herzliya, Israel.
Latest PRFX News From Around the Web
Below are the latest news stories about PAINREFORM LTD that investors may wish to consider to help them evaluate PRFX as an investment opportunity.
PainReform Provides Business Update for the Third Quarter of 2022Implements Technology Improvements Related to PRF-110 Manufacturing Process Ahead of Planned Phase 3 Clinical Trial in BunionectomyTEL AVIV, Israel, Nov. 15, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a business update for the third quarter ended September 30, 2022. Ilan Hadar, Chief Executive Officer of Pain Reform, stated, “We |
PainReform Provides Further Update on Manufacturing of PRF-110TEL AVIV, Israel, Nov. 08, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a further update related to the manufacturing process of clinical batches for PRF-110. Ilan Hadar, Chief Executive Officer of Pain Reform, stated, “As previously announced, we implemented additional enhancements to our manufacturing process for PRF-110 expected |
PainReform Provides PRF-110 Manufacturing UpdateCompleted tech transfer to CMO resulting in new process improvements On track to commence Phase 3 clinical trial in bunionectomy in November 2022 TEL AVIV, Israel, Oct. 04, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided an update regarding the added benefits in its PRF-110 manufacturing process. This new process is expected to not on |
PainReform to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceTEL AVIV, Israel, Sept. 01, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform, will be presenting at the H.C. Wainwright 24th Annual Global Investment Conference which is being held September 12th - 14th, 2022. The event will include virtual participation as well as in-person parti |
PainReform (PRFX) Gets a Buy from Maxim GroupE ratio of -1.23. |
PRFX Price Returns
| 1-mo | -26.97% |
| 3-mo | -39.29% |
| 6-mo | -51.78% |
| 1-year | -73.96% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -66.92% |
| 2021 | -70.25% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...